Savient Pharmaceuticals, Inc. Message Board

Savient Pharmaceuticals, Inc. (SVNT) Given “Buy” Rating by Global Hunter

http://www.americanbankingnews.com/2011/03/27/savient-pharmaceuticals-inc-svnt-given-buy-rating-by-global-hunter-securities-analysts/

Equities research analysts at Global Hunter Securities reiterated a “buy” rating on shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) in a research note to investors on Friday.
Separately, analysts at Zacks Investment Research upgraded shares of Savient Pharmaceuticals, Inc. from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, March 1st.
Shares of Savient Pharmaceuticals, Inc. traded up 2.32% during mid-day trading on Friday, hitting $10.13. Savient Pharmaceuticals, Inc. has a 52 week low of $9.06 and a 52 week high of $23.46. The stock’s 50-day moving average is $9.7 and its 200-day moving average is $13.28. The company has a market cap of $717.9 million.
Savient Pharmaceuticals, Inc. last announced its quarterly results on Friday, February 25th. The company reported $0.01 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.26) EPS by $0.27. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. On average, analysts predict that Savient Pharmaceuticals, Inc. will post $-0.31 EPS next quarter.
Savient Pharmaceuticals, Inc. (Savient) is a specialty biopharmaceutical company focused on developing KRYSTEXXA (pegloticase), or KRYSTEXXA, for the treatment of chronic gout in patients refractory to conventional therapy. The Company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The Company operates within the Specialty Pharmaceutical segment, which includes sales of Oxandrin and oxandrolone, and the research and development activities of KRYSTEXXA. In its replicate randomized, double-blind, placebo-controlled, Phase III clinical trials, KRYSTEXXA, a biologic PEGylated uricase enzyme, demonstrated the normalization of uric acid, complete resolution of tophi, improvement in chronic pain, improvement of physical functioning and decreased frequency of gout flares in patients with chronic gout.